Tu2018 - Novel Formulation of CT-P13 (Infliximab Biosimilar) for Subcutaneous Administration: Initial Results from a Phase I Open-Label Randomized Controlled Trial in Patients with Active Crohn's Disease
2019 ◽
Vol 13
(Supplement_1)
◽
pp. S066-S067
◽
Keyword(s):
2019 ◽
Vol 157
(2)
◽
pp. 440-450.e8
◽
Keyword(s):